Navigation Links
Vaxart Awarded NIH Grant to Support Development of Orally-Delivered H5N1 Avian Influenza Vaccine

SAN FRANCISCO, Sept. 8 /PRNewswire/ -- Vaxart, Inc., a San Francisco biotechnology company developing oral-delivery vaccines, has been awarded a $2.8 million phase II Small Business Innovation Research grant from the National Institute of Allergy and Infectious Disease (National Institutes of Health) to support development of its first product, an orally-delivered vaccine for H5N1 Avian influenza.

"We thank the NIH for funding the further safety and efficacy tests, which, along with our previous successful animal studies, will pave the way towards clinical trials," said Principal Investigator Sean Tucker, Ph.D. The grant runs for a period of three years.

Vaxart has developed a proprietary approach to vaccine creation that, the company believes, will enable it to produce a portfolio of oral-delivery vaccines easily and quickly.

Central to Vaxart's approach is its unique adjuvant, the vaccine component that enhances immune responses. Vaxart uses an adjuvant that works through a "toll-like receptor" (TLR). TLR agents have been widely applied in vaccines and are well accepted as effective immune stimulators. Vaxart's approach employs TLR3 - the only TLR known to be fully active in the gastrointestinal tract - to stimulate a potent immune response when the vaccine is given in a pill instead of being injected.

The second advantage of the Vaxart approach is the ability to use the same vector, or delivery vehicle, across all vaccines. Usually, each vaccine requires a different vehicle, because people who have been vaccinated build antibodies against the vehicle. Later vaccinations using the same vehicle are less effective, as the body attacks the vehicle instead of the disease target. Vaxart has overcome this obstacle and has demonstrated strong immune responses against multiple targets following a series of oral vaccines. Vaxart believes it will be able to produce new vaccines through a standardized low-cost process, with low regulatory risk because data from one vaccine will help establish the safety of others.

The Vaxart Avian Flu Vaccine Program

The recent emergence of pandemic H1N1 flu has underlined the importance of being prepared for pandemic illnesses. Avian flu is an ideal first test for Vaxart's technology, due to its capability to quickly protect people against new threats. In studies completed in 2008, the vaccine successfully protected large animals against death from Avian flu infection.

About Vaxart

Vaxart is a San Francisco biotechnology company developing oral-delivery vaccines. The vaccines incorporate a proprietary adjuvant that boosts the immune response, enabling them to be effective when swallowed in a pill or capsule. Moving forward, Vaxart intends to develop next-generation, oral alternatives to existing vaccines with proven market potential. For more information, visit

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Sean Tucker, Ph.D.

    CONTACT:    Michele Parisi

SOURCE Vaxart, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. UVa researcher awarded $3.6 million grant to fight drug-resistant bacteria
2. Southwest Ambulance Awarded Exclusive, 3-Year Contract Extension in Peoria, Arizona
3. CAS Medical Systems, Inc. Awarded $2.8 Million Grant by National Institutes of Health
4. PartsSource Awarded US Patent for PartsFinder(TM) Application
5. Wrigleys Orbit(R), Extra(R) and Eclipse(R) Sugar-Free Chewing Gums Awarded American Dental Associations Seal of Acceptance
6. Insulet Awarded National Accreditation for Excellence by Community Health Accreditation Program
7. Paragon Technologies SI Systems Brand Awarded A $1.0 Million System Expansion Contract for an Automated Light-Picking System
8. UMASS Medical School awarded National Childrens Study contract
9. beBetter Awarded WV Quitline Contract
10. Henricksen Awarded 2007 Distinguished Veterinary Staff Award
11. Lacey Veterinarian Awarded 2007 WSVMA Recent Graduate Award
Post Your Comments:
(Date:11/27/2015)... , ... November 27, 2015 , ... MPWH, the No.1 Herpes-only dating community in the ... Table 1-1 ). More than 3.7 billion people under the age of 50 ... (HSV-1), according to WHO's first global estimates of HSV-1 infection . , "The data ...
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television ... an interesting show that delves into an array of issues that are presently affecting ... benefit from open dialogue, this show is changing the subjects consumers focus on, one ...
(Date:11/27/2015)... , ... November 27, 2015 , ... CBD College ... of Allied Health Education Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. ... accredited colleges, as only one of twelve colleges and universities in the state of ...
(Date:11/27/2015)... California (PRWEB) , ... November 27, 2015 , ... Avid ... Joplin Ann Arbor Michigan boxing style concert posters. This is one of Joplin's most ... the Canterbury House at the University of Michigan in Ann Arbor. The According to ...
(Date:11/26/2015)... ... 26, 2015 , ... Inevitably when people think Thanksgiving, they also think Holiday ... the Black Friday and Cyber Monday massage chair sales to receive the ... and low to find the best massage chair deals, they can see all of ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... , Pays-Bas, November 27, 2015 ... au traitement photodynamique au Bremachlorin contre le cancer ... approche consistant à combiner l,immunothérapie au traitement photodynamique ... --> Une nouvelle approche consistant ... contre le cancer avancé.    ...
(Date:11/27/2015)... 2015 --> ... online. The potential to save costs, improve treatment quality ... from fully exploited as yet. Here, particular emphasis is ... via mobile tablet or directly at the patients, bedside. ... ) -->      (Photo: ...
(Date:11/27/2015)... Ein neuer Kombinationsansatz vereint ... --> Ein neuer Kombinationsansatz vereint Immuntherapie ... --> Ein neuer Kombinationsansatz vereint Immuntherapie ... Clinical Cancer Research vom 6. November ... vom 6. November 2015 berichtet. --> ...
Breaking Medicine Technology: